Pacer Advisors
RGNX icon

Pacer Advisors’s Regenxbio RGNX Stock Holding History

Pacer Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-587
Closed -$6.87K – 2671
2024
Q2 		$6.87K Sell
587
-248
-30% -$3.86K ﹤0.01% 3606
2024
Q1 		$17.6K Buy
+835
New +$14.9K ﹤0.01% 3468
2021
Q2 		– Sell
-1,914
Closed -$65K – 1532
2021
Q1 		$65K Buy
1,914
+180
+10% +$7.68K ﹤0.01% 1403
2020
Q4 		$79K Sell
1,734
-612
-26% -$21.4K ﹤0.01% 1383
2020
Q3 		$65K Buy
+2,346
New +$76.5K ﹤0.01% 1294
2018
Q4 		– Sell
-3,011
Closed -$227K – 937
2018
Q3 		$227K Buy
+3,011
New +$217K 0.01% 1006
2018
Q1 		– Sell
-450
Closed -$15K – 1112
2017
Q4 		$15K Buy
+450
New +$13.6K ﹤0.01% 1118

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Pacer Advisors's RGNX Position: Q3 2024 in Review

Pacer Advisors sold out of Regenxbio (RGNX) in Q3 2024, closing a stake of 587 shares — an estimated $6.87K sold.

Pacer Advisors first reported a position in RGNX in Q4 2017 and held it in 7 quarters. The position peaked at $227K in Q3 2018. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

  • Pacer Advisors reported no remaining Regenxbio position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 587 Regenxbio shares in Q3 2024, an estimated $6.87K.
  • Pacer Advisors first reported a position in Regenxbio in Q4 2017 and held it in 7 quarters.
  • Pacer Advisors's Regenxbio position peaked at $227K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.